Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Boulet (Québec, QC, Canada), L. Lee (Collegeville, PA, United States of America), H. Kerstjens (Groningen, Netherlands), A. Papi (Ferrara, Italy), A. Zarankaite (Stockley Park West, Uxbridge, Middlesex, United Kingdom), I. Pavord (Oxford, United Kingdom), Z. Bailes (Stockley Park West, Uxbridge, Middlesex, United Kingdom), G. Brusselle (Ghent, Belgium), N. Barnes (Brentford, Middlesex and London, United Kingdom), N. Hanania (Houston, TX, United States of America), S. Pascoe (Collegeville, PA, United States of America), J. Oppenheimer (Newark, NJ, United States of America), E. Pizzichini (Brentford, Middlesex (UK) and Santa Catarina, Brazil), A. Fowler (Stockley Park West, Uxbridge, Middlesex, United Kingdom). CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA. 2631

Member's Comments

No comment yet.

Related content which might interest you: CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020 Year: 2021 Characteristics of prominent response to triple therapy in patients with asthma uncontrolled on ICS/LABA: A stratified analysis of the TRIMARAN and TRIGGER studies Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Influence of age on evolution of asthma control level and treatment compliance under ICS/LABA therapy Source: Eur Respir J 2005; 26: Suppl. 49, 382s Year: 2005 Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020